61 results
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
4 Jun 12
A.P. Pharma Announces Study Finding Continuous Exposure to a
12:00am
Emetic Control
– Phase 3 Data Abstract Accepted by American Society of Clinical Oncology for
Publication at Annual Meeting –
REDWOOD CITY, Calif. – May … results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology’s (ASCO) 2012 Annual Meeting
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
22 Jun 12
A.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study
12:00am
Association of Supportive Care in Cancer and the International Society of Oral Oncology International Symposium –
REDWOOD CITY, Calif. – June 20, 2012 –A.P … Phase 3 trial of APF530 at theMultinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
3 Jul 12
A.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting
12:00am
-Induced Nausea and Vomiting
– Poster at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology … and the International Society of Oral Oncology (MASCC/ISOO) International Symposium in New York. As previously reported, the Phase 3 study showed APF530
8-K
HRTX
Heron Therapeutics Inc
4 Jun 12
A.P. Pharma Announces Study Finding Continuous Exposure to a
12:00am
of APF530 has been published in conjunction with the American Society of Clinical Oncology’s (ASCO) 2012 Annual Meeting.
Item 9.01 Financial
8-K
HRTX
Heron Therapeutics Inc
3 Jul 12
A.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting
12:00am
the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) International Symposium in New
8-K
2v772gj
22 Jun 12
A.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study
12:00am
8-K
EX-99.1
ysl38g 0fnqc1ehhl
28 Oct 19
Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain
8:41am
8-K
EX-99.1
k8txpzs7s8t
5 Aug 09
A.P. Pharma Reports Second Quarter 2009 Financial Results
12:00am
10-K/A
5fbjqlzhj
30 Apr 99
Annual report (amended)
12:00am
DEF 14A
pnvk5
27 Apr 95
Definitive proxy
12:00am
8-K
EX-99.2
fzxb zzvcua7hbxbr5
11 Jan 21
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program
8:40am
PREC14A
84wu 3pjvct
28 Apr 99
Preliminary proxy with contested solicitation
12:00am